

# eGFR Cut-Off for Glucose Lowering Therapies

Consult current SmPC prior to prescribing. Last updated 16/03/2021		CKD Stage 1 (>90)	CKD Stage 2 (60-89)	CKD Stage 3 (30-59)	CKD Stage 4 (15-29)	CKD Stage 5 (<15)	
Other OADs	Glimepiride	No adjustment				Avoid use	
	Repaglinide	No adjustment					
	Pioglitazone*	No adjustment				<4 Cr/Cl	
DPP-4i	Sitagliptin	No adjustment		Lower dosages are recommended (see SmPC)			
	Saxagliptin	No adjustment		2.5 mg/day	Avoid use		
	Vildagliptin	No adjustment		50 mg/day (Cr/Cl <50)			
	Alogliptin	No adjustment		12.5 mg/day	6.25 mg/day		
	Linagliptin	No adjustment					
	Dapagliflozin	Initiate if eGFR > 60ml/min†. Licensed in heart failure and no diabetes.			Limited evidence in heart failure and eGFR <30ml/min		
	Canagliflozin	300mg dose if eGFR > 60ml/min. 100mg down to 45 ml/min if ACR < 30			100mg od if ACR ≥ 30		
SGLT-2	Empagliflozin	Initiate if eGFR > 60ml/min†		Avoid use if eGFR < 45 ml/min			
	Exenatide BID	No adjustment		Careful use	Avoid use		
	Exenatide OV	No adjustment		Avoid use (Cr Cl < 50)			
	Lixisenatide	No adjustment		Careful use	Avoid use		
	GLP-1 RA	Dulaglutide	No adjustment				Avoid use
		Liraglutide	No adjustment				Avoid use
Semaglutide		No adjustment				Avoid use	
Rybelsus – oral Semaglutide		No adjustment				Avoid use	

\*pioglitazone should be avoided in dialysed patients and No dose adjustment is necessary in patients with impaired renal function (creatinine clearance > 4 ml/min);

†Additional licence precautions; \*\*Not launched – Final licence precautions not confirmed.

CKD, chronic kidney disease; DPP-4i, dipeptidyl peptidase-4 inhibitor; eGFR, estimated glomerular filtration rate; GLP-1 RA, glucagon-like peptide-1 receptor agonist; OADs, oral antidiabetics; SGLT-2, sodium glucose co-transporter-2.

■ Indicated  
■ Restrictions apply  
■ Contraindicated

Data derived from respective drug SmPCs. Available at: [www.medicines.org.uk/EMC/medicine/](http://www.medicines.org.uk/EMC/medicine/)